HOME >> BIOLOGY >> NEWS
Study Highlights the Use of Viruses as Tools for Material Science and Drug Delivery

What would you think if your doctor wanted to inject you with a virus as a part of your medical treatment? Though still a long way off, that is just one of the implications of a recent breakthrough by Temple University chemistry professor Trevor Douglas and Montana State University plant pathology professor Mark Young. The results of their research appear in the May 14 issue of Nature.

Douglas and Young have utilized a "gating mechanism" in the protein coats of some simple viruses which allows them to admit and expel organic and inorganic material. Through these "reversible structural transitions" technicians will be able to remove the genetic component of a virus (the DNA or RNA that allows the virus to reproduce) and use the remaining protein coat as a container and delivery system for other substances.

Douglas and Young explain that "In their native state, viruses are protein assemblies which act as host containers for nucleic acid storage and transport. We have subverted this natural function." Their work is, to a large extent, a conceptual breakthrough. To see (and prove) that viruses are substances that can be taken apart, purged of genetic material, reassembled and used as couriers of selected substances is a significant challenge to conventional thinking.

Hope for significant medical advances come from the fact that the two researchers were able to load an organic substance similar to heparin--which is routinely used to treat coronary thrombosis--into cowpea chlorotic mottle virus. Because this phenomenon of gating is possible for a large number of viruses of different shapes and sizes, there is no reason to think that options for drug delivery are limited to any particular class of medicines.

The simple protein coats that Douglas and Young work with can also be "easily and routinely modified by design." This means that the loaded virus can
'"/>

Contact: T. Christopher Bond
tbond@astro.temple.edu
(215) 204-7476
Temple University
13-May-1998


Page: 1 2

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
(Date:10/18/2014)... sample of patients with undiagnosed, suspected genetic conditions, a ... a higher molecular diagnostic yield than traditional molecular diagnostic ... . The study is being released to coincide with ... Exome sequencing, which sequences the protein­coding region of the ... present in a cell or organism), has been rapidly ...
(Date:10/17/2014)... the University of Copenhagen have shown for the first ... of Cystic fibrosis patients, giving them the opportunity to ... chronic infections. , The study also discovered the bacterial ... patients was halted or slowed down by the immune ... the oxygen and helped "suffocate" the bacteria, forcing the ...
(Date:10/16/2014)... Virginia Institute of Marine Science have received a ... to identify the streams and wetlands most vulnerable ... help local governments and citizens conserve these important ... dataset of tidal-marsh observations first gathered by VIMS ... baseline can today,s researchers accurately map the slow ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3
(Date:10/25/2014)... Des Moines, Iowa (PRWEB) October 24, 2014 ... today that Perdue plans to more than double ... in 2015 in geographies supplying its soybean crush ... oil produced from this program will target several ... healthier oil alternatives with good performance. , For ...
(Date:10/25/2014)... 24, 2014 A new way to ... pitfalls of current skin grafting technologies, it also speeds ... The method, outlined in the October issue of STEM ... deep skin injuries that result from severe burns and ... the skin’s regenerative elements. These wounds heal by contraction, ...
(Date:10/25/2014)... 2014 Investor-Edge has initiated coverage ... CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ... Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended on a positive note as the Dow Jones ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
Cached News: